Sativex Clinical Review: Typically 8-12 Sprays Daily, Effective for MS Spasticity and Neuropathic Pain | Research

The takeaway

Clinical development of Sativex showed patients typically self-titrate to 8-12 sprays per day (22-32 mg THC, 20-30 mg CBD), with positive placebo-controlled trial results for MS spasticity and neuropathic pain, leading to Canadian approval.

Read this if you want clinical details about how Sativex is dosed and what trials showed about its effectiveness.

Patients self-titrate to 8-12 sprays daily, receiving approximately 22-32 mg THC and 20-30 mg CBD

What the researchers found

This review covered the clinical development of Sativex, one of the first cannabis-based medicines approved through conventional pharmaceutical pathways. As an oromucosal spray allowing flexible, individualized dosing, patients typically self-titrate to approximately 8-12 sprays per day.

At this dosing, patients receive approximately 22-32 mg THC and 20-30 mg CBD daily. Clinical development focused on MS symptoms (spasticity and neuropathic pain) and neuropathic pain from other causes.

Positive results from placebo-controlled trials demonstrated efficacy and tolerability as add-on therapy for these conditions. Sativex had been approved in Canada for neuropathic pain due to MS, with further approvals expected for spasticity and broader neuropathic pain indications based on ongoing studies.

Why it matters

The self-titration approach to dosing, where patients adjust their own dose based on response and tolerability, became a model for other cannabis-based medicines. The typical daily dose range provides useful reference points for clinical practice.

The numbers in context

Each spray: 2.7 mg THC + 2.5 mg CBD. Typical daily dose: 8-12 sprays. Daily THC: approximately 22-32 mg. Daily CBD: approximately 20-30 mg. Approved in Canada for MS neuropathic pain.

How the study worked

Clinical review of the Sativex development program, covering pharmacology, dosing, clinical trial results, and regulatory status. Focused on placebo-controlled trials for MS symptoms and neuropathic pain.

What this study cannot tell us

This review is from the manufacturer's perspective and focuses on positive results. The self-titration dosing approach means controlled dosing comparisons are difficult. Long-term safety data beyond the trial periods was limited.

How to read the evidence

Clinical review of controlled trials. Provides useful dosing and efficacy information from the pharmaceutical development program.

When this study was published

Published in 2006. Sativex has since been approved in over 25 countries and extensive real-world dosing data is now available.

The bigger picture

Sativex's development demonstrated that cannabis-based medicines could successfully navigate pharmaceutical regulatory processes. The self-titration dosing model acknowledged the wide variability in individual responses to cannabinoids, a challenge that continues to affect cannabis medicine prescribing.

Questions still open

Does the self-titration approach lead to optimal dosing, or do some patients under- or over-dose? How does Sativex compare to other neuropathic pain treatments in terms of efficacy?

Common questions

How much THC and CBD is in each Sativex spray?

Each spray delivers 2.7 mg of THC and 2.5 mg of CBD. Patients typically use 8-12 sprays per day, resulting in approximately 22-32 mg THC and 20-30 mg CBD daily, though the flexible dosing allows individual adjustment.

What conditions has Sativex been approved for?

At the time of this 2006 review, Sativex was approved in Canada for neuropathic pain in MS. It has since been approved in over 25 countries, primarily for MS-related spasticity.

Read the original research

Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.

Expert opinion on pharmacotherapy, 7(5), 607-15

View on PubMed ↗

Citation

Barnes, Michael Philip. (2006). Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.. Expert opinion on pharmacotherapy, 7(5), 607-15.